Anthem Biosciences (NSE:ANTHEM) Total Receivables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANTHEM Anthem Biosciences Ltd NSE:ANTHEM
23 GF Score
Price ₹778.90
! 5 Warning Signs
View Full Analysis

What is Anthem Biosciences Total Receivables?

Anthem Biosciences NSE:ANTHEM -1.60% 23 Total Receivables is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ANTHEM with a GF Score™ of 23/100. The stock has 5 warning signs investors should review.

Anthem Biosciences's Total Receivables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Anthem Biosciences Total Receivables Related Terms

Anthem Biosciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Anthem Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences Total Receivables Chart

Anthem Biosciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
3,335.17 2,752.84 4,906.44 4,599.11 5,935.03

Anthem Biosciences Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 5,773.38 0.00 5,935.03 0.00
NSE:ANTHEM
23GF Score
Anthem Biosciences Ltd NSE:ANTHEM
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anthem Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹0 Mil mean?
Anthem Biosciences (NSE:ANTHEM) has a Total Receivables of ₹0 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Anthem Biosciences and its competitors.
Is Anthem Biosciences' Total Receivables too high?
Anthem Biosciences' current Total Receivables is ₹0 Mil. Overall, Anthem Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Total Receivables compare to VRTX and REGN?
Anthem Biosciences' Total Receivables of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current Total Receivables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Total Receivables of ₹0 Mil. The current Total Receivables is ₹0 Mil. Anthem Biosciences' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Total Receivables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthem Biosciences Business Description

Other Exchanges 544449:India
Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, KA, IND, 560 099
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
23GF Score

Get the complete analysis for NSE:ANTHEM

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹778.90
Price